Literature DB >> 14579164

Bone mineral density changes in women with systemic lupus erythematosus.

M Boyanov1, R Robeva, P Popivanov.   

Abstract

The aim of this study was to analyse the heterogeneity of bone mineral density (BMD) reduction across measurement sites in female systemic lupus erythematosus (SLE) patients on glucocorticoid (CS) treatment. The study population consisted of two subgroups: 32 women at a mean (SD) age of 43.2 (12.0) years, SLE duration of 13.4 (6.2) years, treated with a mean cumulative prednisone dose of 34.4 g; and 16 women at a mean age of 36.1 (9.0) years, SLE duration of 3.2 (2.0) years, never treated with glucocorticoids (control group). The participants underwent a standardised interview, medical record review, blood sampling and BMD examination of the lumbar spine, femoral neck and distal forearm by dual-energy X-ray absorptiometry. CS-treated participants were supplemented with daily calcium (1200 mg) and vitamin D (500 UI). During the study mean daily glucocorticoid dose was 10 mg prednisone equivalent. The controls did not receive either corticosteroids or calcium and vitamin D. BMD and laboratory parameters were re-examined at the end of the second year. At baseline 22 (68.7%) of the CS-treated participants had osteoporosis at least at one major site, compared to 18.8% of the controls. The BMD reduction was proportional to the trabecular bone content at the specific measurement site. At baseline mean T scores in the CS-treated group were the highest at the forearm (-1.03 +/- 1.13), followed by the hip (-1.32 +/- 1.26), AP spine (-1.87 +/- 1.46) and lateral spine (-2.90 +/- 1.50). At follow-up lateral spine bone loss was 5.54% per year, the total hip and the forearm lost 3.59% and 0.33%, respectively, compared to annual losses of 1.02% (AP spine), 1.30% (lateral spine), 0.83% (total hip) and 0.11% (forearm) in the control group. The heterogeneity of BMD reduction in our SLE population emphasises the need for the targeted use of bone densitometry in steroid-treated patients. Attention should be paid to trabecular-rich sites, and fracture risk should be specifically determined.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14579164     DOI: 10.1007/s10067-003-0743-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  19 in total

Review 1.  Bone health and systemic lupus erythematosus.

Authors:  Chin Lee; Rosalind Ramsey-Goldman
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

2.  Lower P1NP serum levels: a predictive marker of bone loss after 1 year follow-up in premenopausal systemic lupus erythematosus patients.

Authors:  L P C Seguro; C B Casella; V F Caparbo; R M Oliveira; A Bonfa; E Bonfa; R M R Pereira
Journal:  Osteoporos Int       Date:  2014-08-22       Impact factor: 4.507

3.  Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus.

Authors:  J Jacobs; L-A Korswagen; A M Schilder; L H van Tuyl; B A C Dijkmans; W F Lems; A E Voskuyl; I E M Bultink
Journal:  Osteoporos Int       Date:  2012-10-03       Impact factor: 4.507

Review 4.  Clinical utilities of quantitative ultrasound in osteoporosis associated with inflammatory rheumatic diseases.

Authors:  Win Min Oo; Vasikaran Naganathan; Myat Thae Bo; David J Hunter
Journal:  Quant Imaging Med Surg       Date:  2018-02

5.  Cortical thinning and progressive cortical porosity in female patients with systemic lupus erythematosus on long-term glucocorticoids: a 2-year case-control study.

Authors:  T Y Zhu; J F Griffith; L Qin; V W Y Hung; T-N Fong; S-K Au; X-L Tang; E W Kun; A W Kwok; P-C Leung; E K Li; L-S Tam
Journal:  Osteoporos Int       Date:  2015-03-04       Impact factor: 4.507

6.  A Retrospective Analysis of Longitudinal Changes in Bone Mineral Density in Women with Systemic Lupus Erythematosus.

Authors:  Claudia Mendoza-Pinto; Mario García-Carrasco; Daniela Juárez-Melchor; Pamela Munguía-Realpozo; Ivet Etchegaray-Morales; Nicolás Santiago-Martín; Jorge Ayón-Aguilar; Socorro Méndez-Martínez
Journal:  Calcif Tissue Int       Date:  2021-04-17       Impact factor: 4.333

Review 7.  Bone health in systemic lupus erythematosus.

Authors:  Pantelis Panopalis; Jinoos Yazdany
Journal:  Curr Rheumatol Rep       Date:  2009-07       Impact factor: 4.592

8.  Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus.

Authors:  Claudia Mendoza-Pinto; Mario García-Carrasco; Hilda Sandoval-Cruz; Ricardo O Escárcega; Mario Jiménez-Hernández; Ivet Etchegaray-Morales; Elena Soto-Vega; Margarita Muñoz-Guarneros; Aurelio López-Colombo; Margarita Delezé-Hinojosa; Ricard Cervera
Journal:  Clin Rheumatol       Date:  2008-08-01       Impact factor: 2.980

Review 9.  Glucocorticoid-induced osteoporosis in rheumatic diseases.

Authors:  Rosa Maria Rodrigues Pereira; Jozélio Freire de Carvalho; Ernesto Canalis
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

10.  Dickkopf-1 (Dkk-1) serum levels in systemic sclerosis and rheumatoid arthritis patients: correlation with the Trabecular Bone Score (TBS).

Authors:  Barbara Ruaro; Andrea Casabella; Sabrina Paolino; Carmen Pizzorni; Massimo Ghio; Chiara Seriolo; Luigi Molfetta; Patrizio Odetti; Vanessa Smith; Maurizio Cutolo
Journal:  Clin Rheumatol       Date:  2018-10-06       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.